331 related articles for article (PubMed ID: 23636448)
1. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.
Verheijen RB; Beijnen JH; Schellens JHM; Huitema ADR; Steeghs N
Clin Pharmacokinet; 2017 Sep; 56(9):987-997. PubMed ID: 28185218
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
Johnson FM; Agrawal S; Burris H; Rosen L; Dhillon N; Hong D; Blackwood-Chirchir A; Luo FR; Sy O; Kaul S; Chiappori AA
Cancer; 2010 Mar; 116(6):1582-91. PubMed ID: 20108303
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.
Deng Y; Sychterz C; Suttle AB; Dar MM; Bershas D; Negash K; Qian Y; Chen EP; Gorycki PD; Ho MY
Xenobiotica; 2013 May; 43(5):443-53. PubMed ID: 23548165
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
10. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
[TBL] [Abstract][Full Text] [Related]
11. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.
van Giersbergen PL; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2002 Jun; 53(6):589-95. PubMed ID: 12047483
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
Heath EI; Infante J; Lewis LD; Luu T; Stephenson J; Tan AR; Kasubhai S; LoRusso P; Ma B; Suttle AB; Kleha JF; Ball HA; Dar MM
Cancer Chemother Pharmacol; 2013 Mar; 71(3):565-73. PubMed ID: 23344712
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Shibata SI; Chung V; Synold TW; Longmate JA; Suttle AB; Ottesen LH; Lenz HJ; Kummar S; Harvey RD; Hamilton AL; O'Neil BH; Sarantopoulos J; LoRusso P; Rudek MA; Dowlati A; Mulkerin DL; Belani CP; Gandhi L; Lau SC; Ivy SP; Newman EM
Clin Cancer Res; 2013 Jul; 19(13):3631-9. PubMed ID: 23653147
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.
Atsmon J; Dingemanse J; Shaikevich D; Volokhov I; Sidharta PN
Clin Pharmacokinet; 2013 Aug; 52(8):685-92. PubMed ID: 23568224
[TBL] [Abstract][Full Text] [Related]
15. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
Salem AH; Yang J; Graham A; Patnaik A; Holen K; Pradhan R; Xiong H
Anticancer Res; 2014 Apr; 34(4):2001-6. PubMed ID: 24692738
[TBL] [Abstract][Full Text] [Related]
16. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
[TBL] [Abstract][Full Text] [Related]
17. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib.
Yin OQ; Gallagher N; Fischer D; Demirhan E; Zhou W; Golor G; Schran H
J Clin Pharmacol; 2010 Aug; 50(8):960-7. PubMed ID: 20498287
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Dy GK; Infante JR; Eckhardt SG; Novello S; Ma WW; Jones SF; Huff A; Wang Q; Suttle AB; Ottesen LH; Adjei AA; Burris HA
Invest New Drugs; 2013 Aug; 31(4):891-9. PubMed ID: 23135778
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Lassen U; Miller WH; Hotte S; Evans TR; Kollmansberger C; Adamson D; Nielsen DL; Spicer J; Chen E; Meyer T; Brown K; Rafi R; Sawyer MB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):543-9. PubMed ID: 23196640
[TBL] [Abstract][Full Text] [Related]
20. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
